Nuvectis Pharma, Inc. (NVCT) Earnings Call Transcripts
Nuvectis Pharma, Inc.'s Latest Earnings Call - June 22, 2026
In Q2 2026, Nuvectis Pharma announced a strategic portfolio expansion through an in-licensing deal with Haisco Pharmaceutical Group for two drug candidates, NXP100 and NXP200. This move transforms Nuvectis into a late-stage development company, focusing on complement-mediated diseases and oncology. The company did not report specific revenue or earnings figures in this call, nor did it provide updated financial guidance. However, the strategic deal and the potential market impact of these drug candidates could significantly influence the stock's trajectory.
Reported metrics
| Metric | Value |
|---|---|
| Upfront and Near-Term Payments | $40 million (neutral) |
| Potential Additional Payments | $1.4 billion (neutral) |
| Patent Expiry for NXP100 | 2043 (neutral) |
| Patent Expiry for NXP200 | 2042 (neutral) |
Guidance from management
Management did not provide specific financial guidance but highlighted expected catalysts from China, including potential drug approvals for NXP100 in PNH.
What analysts pressed on
Analysts may express concerns about the execution risks associated with the development and commercialization of NXP100 and NXP200, especially given the competitive landscape in complement-mediated diseases and oncology.
Main topics on the call
- Strategic In-Licensing Deal — Nuvectis Pharma announced a strategic in-licensing deal with Haisco Pharmaceutical Group for global ex-China rights to NXP100 and NXP200. This deal positions Nuvectis as a late-stage development company. Management state...
- NXP100 Development — NXP100, a Complement Factor B inhibitor, is in late-stage development for PNH and IgA nephropathy. It has shown superiority over SOLIRIS in head-to-head trials. Management highlighted, 'NXP100 is currently the subject of...
- NXP200 Oncology Pipeline — NXP200, a paradox breaker BRAF inhibitor, has demonstrated single-agent activity across multiple tumor types. It is currently in a Phase Ib study in China. Management noted, 'NXP200 has demonstrated single-agent activity...
- Intellectual Property Protection — NXP100 and NXP200 have strong IP protection with composition of matter patents expiring in 2043 and 2042, respectively. Management emphasized the strategic importance of this protection.
Read the full Nuvectis Pharma, Inc. transcript (June 22, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. (NVCT) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 1 call on record spanning June 22, 2026 to June 22, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 1 Nuvectis Pharma, Inc. earnings call transcript on record, spanning June 22, 2026 to June 22, 2026. The most recent call on file is dated June 22, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- NVCT
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 1
- First call
- June 22, 2026
- Most recent
- June 22, 2026
| Quarter | Date | |
|---|---|---|
| Special Calls | Jun 22, 2026 | Read transcript → |